Lytix Biopharma ASA (OB: LYTIX)
Health Care · Biotechnology · NO
Nkr7.70
+2.67% today · -19.5% 1Y
Lytix Biopharma ASA (OB: LYTIX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $62.00M and employs 14 people.
Over the last twelve months the share price has lost 19.5%, trading between 6.68 and 11.90.
Tweenvest scores Lytix Biopharma ASA across four factors: quality 28/100. Its strongest factor is quality.
LYTIX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $62.00M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- -0.49
- 52-week high
- Nkr11.90
- 52-week low
- Nkr6.68
- Avg volume (3M)
- —
- Shares outstanding
- 76.90M
- Employees
- 14
- Next earnings
- —
About Lytix Biopharma ASA
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
- ISIN
- NO0010405780
- Founded
- 2003
- Listed since
- Jun 14, 2021
- Exchange
- Oslo Bors
- Currency
- NOK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.53 | -1.60% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.78 | -0.67% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $548.74 | -0.74% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $827.02 | -0.78% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.61 | -2.03% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.